

Freedom of Information Request: Our Reference CTMUHB_30_24

You asked:

Could you please tell me how many of the following intra-vitreous injections/implants has your trust administered in the four-month period from September to December 2023:

- Aflibercept
- Bevacizumab – Avastin
- Bevacizumab – Biosimilar
- Brolucizumab
- Dexamethasone
- Faricimab
- Fluocinolone acetonide
- Ranibizumab - Lucentis (pre-filled syringes)
- Ranibizumab - Lucentis (vials)
- Ranibizumab – Ongavia

Our response:

The total administrations of intra-vitreous injections/implants within Cwm Taf Morgannwg University during the period September to December 2023 are as follows:

• Aflibercept	1829
• Bevacizumab – Avastin	0
• Bevacizumab – Biosimilar	15
• Brolucizumab	0
• Dexamethasone	60
• Faricimab	729
• Fluocinolone acetonide	0
• Ranibizumab - Lucentis (pre-filled syringes)	9
• Ranibizumab - Lucentis (vials)	0
• Ranibizumab – Ongavia	0